Quintrio
Home

PHARMACEUTICAL PREPARATIONS

FibroBiologics, Inc. Common Stock

FBLG

FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.

Last trade $0.91
Day change +$0.0066 (+0.73%)
Day range $0.898 – $0.952
Volume 61,557
Market cap $6M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.37M
Price / earnings
—
Price / book
1.37×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.18×

Profitability

Earnings per share
-$2.56
Return on assets
-228.77%
Return on equity
-391.26%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.64×
Quick ratio
2.64×
Cash ratio
1.59×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$14.8M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for FBLG, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.38M$2.12M$1.79M$2.25M$2.45M$2.75M$2.36M$2.14M
Research and development$1.66M$2.95M$797K$2.79M$2.04M$1.78M$1.36M$1.21M
Total operating expenses$4.03M$5.07M$2.59M$5.04M$4.49M$4.53M$3.71M$3.35M
Operating income-$4.03M-$5.07M-$2.59M-$5.04M-$4.49M-$4.53M-$3.71M-$3.35M
Interest expense-$7K-$4K-$204K$0$0$0-$6K-$5K
Income before taxes-$4.12M-$5M-$3.24M-$5.78M-$4.66M-$4.97M-$3.1M-$500K
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.12M-$5M-$3.24M-$5.78M-$4.66M-$4.97M-$3.1M-$500K
Net income attributable to common shareholders-$4.12M-$5M-$3.24M-$5.78M-$4.66M-$4.97M-$3.1M-$500K
EBITDA-$3.97M-$5M-$1.94M-$4.97M-$4.43M-$4.48M-$3.25M-$3.31M
Basic earnings per share-$0.66-$1.33-$1.08-$2.60-$2.41-$2.71-$1.82-$0.20
Diluted earnings per share-$0.66-$1.33-$1.08-$2.60-$2.41-$2.71-$1.82-$0.20

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

FibroBiologics announced completion of cGMP manufacturing for CYWC628 drug product and site onboarding for a phase 1/2 clinical trial in diabetic foot ulcers, with first patient dosing expected in Q2 2026. The company reported positive preclinical results for burn and degenerative disc disease programs, raised $3M in capital, and regained full Nasdaq compliance. Q1 2026 showed R&D expenses of $3.0M and a net loss of $5.0M, with cash reserves of $1.5M at quarter-end.

GlobeNewswire Inc.

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.

GlobeNewswire Inc.

FibroBiologics Announces Pricing of $3 Million Public Offering

FibroBiologics priced a public offering of 2.27 million shares and warrants at $1.32 per share, expecting to raise approximately $3 million in gross proceeds before fees. The company also announced successful manufacturing of CYWC628 drug product to support an upcoming diabetic foot ulcer clinical trial. Additionally, the company completed a reverse stock split to regain Nasdaq compliance with bid price requirements.

Benzinga

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

The global cell therapy market is projected to surpass $8.2 billion in 2026, with CAR T-cell therapy expanding at 18% annually. Several companies are advancing manufacturing milestones and clinical breakthroughs: Avaí Bio initiated Master Cell Bank production for α-Klotho anti-aging therapy; FibroBiologics secured a patent for fibroblast cell therapy for osteoporosis; Fate Therapeutics achieved same-day hospital discharge for off-the-shelf CAR T-cell patients; Mesoblast presented favorable survival data for Ryoncil® in graft-versus-host disease; and Longeveron published Phase 2b results showing stem cell therapy improved physical condition in age-related frailty patients.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 30, 20261-for-20reverse split